Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. 

Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: a post-hoc study

First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis.

Time to onset of sustained ≥50% responder status in patients with focal (partial-onset) seizures in three phase 3 studies of adjunctive brivaracetam treatment

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. 

Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: pooled results from three phase 3 studies

Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: a pooled analysis from three phase 3 studies

Reinduction with certolizumab pegol in patients with Crohn’s disease experiencing disease exacerbation: 7-year data from the PRECiSE 4 study. 

Safety of long-term treatment with certolizumab pegol in patients with Crohn’s disease, based on a pooled analysis of data from clinical trials. 

Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies